Melbourne, Australia and Severna Park, MD, USA – 28 October...

Melbourne, Australia and Severna Park, MD, USA – 28 October 2013: The Chief Executive Officer of
medical technology company iSonea Ltd (ASX: ISN) will present at a prestigious Australian biotechnology
investment conference in Melbourne, beginning today.
Mr Michael Thomas will outline the mobile health opportunity presented by iSonea at the Australia
Biotech Invest 2013 event at the Melbourne Convention and Exhibition Centre. He is scheduled to
present Tuesday 29 October at 12.16 pm.
This conference is Australia’s biggest biotech investment event to date and brings together hundreds of
biotech investors, big pharma representatives and industry analysts. It is regarded a premium
opportunity for biotech companies from the Asia-Pacific region to present an investment case and
attract funding.
Mr Thomas commented: “iSonea is a novel company in the healthcare arena, with AirSonea™, a first in
class mobile health technology for asthma sufferers that is in market. Further, we have an ambitious
strategy to leverage the existing technology to create further innovative products and investor value.
“We look forward to presenting this investment case to a global audience and further cementing our
reputation as mobile health pioneers.”
iSonea launched its AsthmaSense™ mobile health smartphone application in June last year and its
AirSonea device in Australia last month. This technology builds on the company’s proprietary acoustic
respiratory monitoring (ARM™) technologies and enables patients with asthma or other respiratory
disorders to monitor their wheeze rates via smartphone technology for the first time. The AirSonea is on
track for US launch in 2014.